| octreotide acetate / Generic mfg. |
CTR20221314: To compare the safety and efficacy of lutetium [177Lu] oxyoctreotide injection versus long-acting octreotide in patients with inoperable or metastatic, progressive, well-differentiated (G1 and G2), somatostatin receptor-positive gastroenteropancreatic neu |
|
|
| Ongoing | 3 | 213 | China | octreotide acetate solution for injection - Generic mfg. | Beijing Xiantong International Pharmaceutical Technology Co., Ltd | Unresectable or metastatic, progressive, well-differentiated (G1 and G2) and somatostatin receptor-positive adult patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). | | | | |
NCT00006269: Octreotide in the Prevention of Diarrhea in Patients Receiving Irinotecan for Metastatic Colon Cancer |
|
|
| Terminated | 3 | 89 | US | irinotecan hydrochloride, octreotide acetate | Novartis | Colorectal Cancer, Diarrhea | 12/99 | | | |
NCT00128232: Safety and Efficacy of Octreotide Long Acting Release (LAR) in Treatment Naïve Acromegalic Patients |
|
|
| Completed | 3 | 100 | Europe | Octreotide LAR | Novartis | Acromegaly | 08/04 | | | |
NCT00092287 / 2004-001091-40: Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome |
|
|
| Terminated | 3 | 4 | US | lanreotide Autogel (somatostatin analogue), Sandostatin long acting release (LAR) Depot (somatostatin analogue) | Ipsen | Malignant Carcinoid Syndrome | | 10/04 | | |
NCT00225979: Safety and Efficacy of Long-acting Repeatable Octreotide Acetate for Injectable Suspension vs. Surgery in Treatment-naïve Patients With Acromegaly |
|
|
| Completed | 3 | 100 | Europe | Octreotide LAR, SMS995 | Novartis Pharmaceuticals | Acromegaly | 03/05 | 03/05 | | |
NCT00241020: Evaluation of the Efficacy of Long-acting Release Octreotide in Patients With Advanced Hepatocellular Carcinoma |
|
|
| Completed | 3 | 270 | Europe | Octreotide | Novartis Pharmaceuticals | Advanced Hepatocellular Carcinoma | 10/05 | 10/05 | | |
| Completed | 3 | 28 | Europe | Octreotide acetate 30 mg suspension, Sandostatin LAR | Novartis Pharmaceuticals | Acromegaly | 10/07 | 10/07 | | |
NCT00444873: Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly |
|
|
| Completed | 3 | 38 | Europe | lanreotide (Autogel formulation), duration of treatment 24-56 weeks, depending on dose interval | Ipsen | Acromegaly | 01/08 | 01/08 | | |
| Completed | 3 | 65 | Europe, RoW | C2L-OCT-01 PR, 30 mg, Octreotide acetate prolonged release, 30 mg, Sandostatin LAR, 30 mg | Ambrilia Biopharma, Inc. | Acromegaly | 02/08 | 02/08 | | |
| Completed | 3 | 429 | US, Canada, Europe, RoW | Octreotide, Sandostatin LAR® Depot, Placebo, Everolimus, RAD001 | Novartis Pharmaceuticals | Carcinoid Tumor, Malignant Carcinoid Syndrome | 04/10 | 06/13 | | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Completed | 3 | 139 | RoW | Octreotide Long Acting Release, Octreotide LAR, Sandostatin LAR, Standard Treatment | Novartis Pharmaceuticals | Chemotherapy-induced Diarrhea | 09/10 | 09/10 | | |
| Terminated | 3 | 169 | US, Europe, RoW | Octreotide Implant, somatostatin analogue, Sandostatin LAR Depot | Endo Pharmaceuticals | Acromegaly | 02/11 | 06/11 | | |
NCT00690430 / 2007-000739-25: Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease |
|
|
| Completed | 3 | 186 | US, Canada, Europe, RoW | Pasireotide, SOM230, Octreotide, Sadostatin LAR | Novartis Pharmaceuticals | Symptomatic Refractory Resistant Carcinoid Disease | 04/12 | 04/12 | | |
PAOLA, NCT01137682 / 2009-016722-13: Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly |
|
|
| Completed | 3 | 198 | US, Canada, Europe, RoW | Pasireotide, SOM230, octreotide LAR 30mg, lanreotide ATG 120mg | Novartis Pharmaceuticals | Acromegaly | 01/13 | 02/17 | | |
NETTER-1, NCT01578239 / 2011-005049-11: A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours |
|
|
| Completed | 3 | 231 | Europe, US | Octreotide LAR, SANDOSTATIN LAR, Octreotide, 177Lu-DOTA0-Tyr3-Octreotate, Lutathera | Advanced Accelerator Applications | Carcinoid Tumor of the Small Bowel, Neuroendocrine Tumour | 07/15 | 01/21 | | |
| Completed | 3 | 358 | US, Canada, Europe, RoW | Pasireotide, SOM230, Octreotide | Novartis Pharmaceuticals | Acromegaly | 03/16 | 03/16 | | |
2022-000507-12: A randomized, controlled, open-label study of RYZ101 compared with standard of care therapy in subjects with inoperable, advanced, SSTR+ well-differentiated GEP-NET that has progressed following 177Lu SSA therapy Ensayo aleatorizado, controlado y abierto de RYZ101 frente al tratamiento habitual en sujetos con tumores neuroendocrinos gastroenteropancreáticos bien diferenciados SSTR+, avanzados e inoperables, que hayan progresado tras tratamiento con 177Lu SSA. |
|
|
| Not yet recruiting | 3 | 288 | Europe | RYZ101, Sunitinib, RYZ101, Sunitinib, L01XE04, Solution for injection, Tablet, Capsule, hard, Powder and solvent for suspension for injection, Solution for injection in pre-filled syringe, Everolimus Zentiva 5mg Tabletten, Szunitinib Mylan 12,5 mg, Sandostatin® LAR®- Monatsdepot 30 mg powder and solvent for suspension for injection, SOMATULINE AUTOGEL 120 mg solution for injection in a pre-filled syringe, Szunitinib Sandoz 12,5 mg | RayzeBio, Inc., RayzeBio, Inc. | gastro-enteropancreatic neuroendocrine tumors (GEP-NETs) Tumores neuroendocrinos gastroenteropancreáticos, gastro-enteropancreatic neuroendocrine tumors (GEP-NETs) Tumores neuroendocrinos gastroenteropancreáticos, Diseases [C] - Cancer [C04] | | | | |
| Active, not recruiting | 3 | 226 | Europe, Canada, US, RoW | Lutathera, long-acting octreotide, high dose long-acting octreotide, Optional post-progression re-treatment with Lutathera, Optional post-progression cross-over to Lutathera, Optional post-progression re-treatment with Lutathera after cross-over | Advanced Accelerator Applications | Gastro-enteropancreatic Neuroendocrine Tumor | 07/23 | 10/27 | | |
| Active, not recruiting | 3 | 332 | Europe, Canada, US, RoW | CAM2029, Octreotide LAR, Lanreotide ATG | Camurus AB | Gastro-enteropancreatic Neuroendocrine Tumor | 12/24 | 12/26 | | |
NCT05459844: A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs |
|
|
| Recruiting | 3 | 196 | RoW | Lutetium[177Lu] Oxodotreotide Injection, 177Lu-DOTA0-Tyr3-Octreotate, Octreotide LAR, SANDOSTATIN LAR, Octreotide | Sinotau Pharmaceutical Group | Neuroendocrine Tumors | 12/24 | 12/28 | | |
ACTION-1, NCT05477576: Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy |
|
|
| Active, not recruiting | 3 | 288 | Europe, Canada, US, RoW | RYZ101, Everolimus 10 mg, Sunitinib 37.5 MG, Octreotide LAR 60 MG Injection, Lanreotide 120Mg Sa Susp Inj Syringe | RayzeBio, Inc. | GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors, Carcinoid, Carcinoid Tumor, Pancreatic NET | 07/25 | 07/28 | | |
NCT05884255: An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors. |
|
|
| Recruiting | 3 | 220 | RoW | Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide, long-acting Octreotide. | Jiangsu HengRui Medicine Co., Ltd. | Advanced Gastroenteropancreatic Neuroendocrine Tumor | 12/26 | 10/30 | | |
NCT00240045: The Use of Drugs to Improve Kidney Function in Patients With Liver and Kidney Dysfunction |
|
|
| Completed | 2/3 | 9 | Canada | Midodrine, albumin, octreotide LAR, midodrine, octreotide, albumin | University of Alberta, Novartis | Type 2 Hepatorenal Syndrome, Refractory Ascites | | 07/07 | | |
| Completed | 2/3 | 42 | US | Octreotide, Octreotide LAR® Depot, Placebo, Placebo injection | Mayo Clinic, Novartis, National Center for Research Resources (NCRR) | Polycystic Kidney, Autosomal Dominant, Polycystic Liver Disease, Hepatomegaly, Liver Diseases, Kidney, Polycystic, Abdominal Pain | 10/08 | 10/08 | | |
NCT01744249 / 2011-001550-29: Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas |
|
|
| Active, not recruiting | 2/3 | 255 | Europe | Axitinib, Sandostatin LAR, Placebo | Grupo Espanol de Tumores Neuroendocrinos, Pfizer | Neuroendocrine Tumors, Advanced Cancer | 08/21 | 10/21 | | |
